Key result
Neprilysin inhibition shows potential to prevent myocardial ischemia-reperfusion injury in STEMI patients.
Why the study?
Mortality and left ventricle remodeling remain substantial in reperfused-STEMI patients, and there is currently no effective therapy for preventing myocardial ischemia-reperfusion injury.
Does neprilysin inhibition prevent myocardial ischemia-reperfusion injury in STEMI patients undergoing reperfusion?
Does neprilysin inhibition prevent myocardial ischemia-reperfusion injury in STEMI patients undergoing reperfusion?
Answers are grounded in this paper and cite their sources.
This review highlights the potential of neprilysin inhibition as a multi-targeted cardioprotective strategy to prevent myocardial ischemia-reperfusion injury in STEMI patients.
During the last three decades, timely myocardial reperfusion using either thrombolytic therapy or primary percutaneous intervention (pPCI) has allowed amazing improvements in outcomes with a more than halving in 1-year ST-elevation myocardial infarction (STEMI) mortality. However, mortality and left ventricle (LV) remodeling remain substantial in these patients. As such, novel therapeutic interventions are required to reduce myocardial infarction size, preserve LV systolic function, and improve survival in reperfused-STEMI patients. Myocardial ischemia-reperfusion injury (MIRI) prevention represents the main goal to reach in order to reduce STEMI mortality. There is currently no effective therapy for MIRI prevention in STEMI patients. A significant reason for the weak and inconsistent results obtained in this field may be the presence of multiple, partially redundant, mechanisms of cell death during ischemia-reperfusion, whose relative importance may depend on the conditions. Therefore, it is always more recognized that it is important to consider a "multi-targeted cardioprotective therapy", defined as an additive or synergistic cardioprotective agents or interventions directed to distinct targets with different timing of application (before, during, or after pPCI). Given that some neprilysin (NEP) substrates (natriuretic peptides, angiotensin II, bradykinin, apelins, substance P, and adrenomedullin) exert a cardioprotective effect against ischemia-reperfusion injury, it is conceivable that antagonism of proteolytic activity by this enzyme may be considered in a multi-targeted strategy for MIRI prevention. In this review, by starting from main pathophysiological mechanisms promoting MIRI, we discuss cardioprotective effects of NEP substrates and the potential benefit of NEP pharmacological inhibition in MIRI prevention.
No takes yet. Share an insight, caveat, or question.
Bellis et al. (2020) conducted a review in ST-elevation myocardial infarction (STEMI) and myocardial ischemia-reperfusion injury (MIRI). Neprilysin (NEP) inhibition was evaluated. Neprilysin pharmacological inhibition is proposed as a potential multi-targeted cardioprotective strategy for the prevention of myocardial ischemia-reperfusion injury in STEMI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: